TSE:4519Pharmaceuticals
Chugai Pharmaceutical (TSE:4519) Stock Net Margin Strength Challenges Cost Pressure Concerns
Chugai Pharmaceutical (TSE:4519) has reported Q2 2026 revenue of ¥341,584 million and basic EPS of ¥70.69, while trailing twelve month revenue stands at ¥1.3 trillion and EPS at ¥286.43, framed by earnings growth of 19.2% over the past year. The company has seen quarterly revenue move from ¥290,004 million and EPS of ¥59.04 in Q2 2025 to ¥341,584 million and EPS of ¥70.69 in Q2 2026, with trailing twelve month EPS rising from ¥240.31 to ¥286.43 over the same comparison points. Together with a...